PARP Inhibitor Pamiparib Under Review in China to Treat Advanced Ovarian Cancer

PARP Inhibitor Pamiparib Under Review in China to Treat Advanced Ovarian Cancer
China's regulatory agency has agreed to consider a request that pamiparib, BeiGene's investigational PARP inhibitor, be approved to treat people with advanced ovarian cancers after at least two prior lines of chemotherapy. The company's new drug application (NDA), submitted to the Center for Drug Evaluation of the Chinese National Medical Products Administration, is specifically for patients with ovarian, fallopian tube, or primary peritoneal cancer whose tumors have, or are thought to have, mutations in BRCA, a DNA repair gene. “This is our first NDA filing for pamiparib, which was discovered by BeiGene and is being developed as both a monotherapy and in combination with other agents, including our own anti-PD1 antibody, tislelizumab,” Yong Ben, MD, chief medical officer of Immuno-Oncology at BeiGene, said in a
Subscribe or to access all post and page content.